Stockreport

Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the ESMO Congress 2025

Perspective Therapeutics, Inc.  (CATX) 
PDF Updated interim results with an additional ~19 weeks of follow-up since the prior update [212Pb]VMT-a-NET continues to be well-tolerated Objective Response Rate of 44% ( [Read more]